[
  {
    "ts": "2026-02-23T02:23:49+00:00",
    "headline": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has […]",
    "url": "https://finance.yahoo.com/news/barclays-takes-neutral-stance-gilead-022349658.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3958fca3-186b-37b8-b756-2311c4075b52",
      "content": {
        "id": "3958fca3-186b-37b8-b756-2311c4075b52",
        "contentType": "STORY",
        "title": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has […]",
        "pubDate": "2026-02-23T02:23:49Z",
        "displayTime": "2026-02-23T02:23:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ha22PhpGlsEhK3tmOzGDVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CkBvnQJGKRIUyIDAWZszGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/barclays-takes-neutral-stance-gilead-022349658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/barclays-takes-neutral-stance-gilead-022349658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BCS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:15:41+00:00",
    "headline": "Gilead to acquire Arcellx for $7.8 billion",
    "summary": "Feb 23 () - Gilead Sciences said ‌on Monday it ‌will buy cancer therapy ​developer Arcellx for an implied equity value of $7.8 ‌billion, ⁠sending shares of Arcellx climbing ⁠77.",
    "url": "https://finance.yahoo.com/news/gilead-acquire-arcellx-7-8-111541314.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "e7d81dc8-c589-3573-99c8-7a644ef8bca0",
      "content": {
        "id": "e7d81dc8-c589-3573-99c8-7a644ef8bca0",
        "contentType": "STORY",
        "title": "Gilead to acquire Arcellx for $7.8 billion",
        "description": "",
        "summary": "Feb 23 () - Gilead Sciences said ‌on Monday it ‌will buy cancer therapy ​developer Arcellx for an implied equity value of $7.8 ‌billion, ⁠sending shares of Arcellx climbing ⁠77.",
        "pubDate": "2026-02-23T11:15:41Z",
        "displayTime": "2026-02-23T11:15:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/4d1704d0b159fd01bb66e5955f523af9",
          "originalWidth": 800,
          "originalHeight": 489,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V8FcAZ2HZF4nFOT4yy2xaw--~B/aD00ODk7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4d1704d0b159fd01bb66e5955f523af9.cf.webp",
              "width": 800,
              "height": 489,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VLfrg2QcYqhyDCV5I9n6zg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4d1704d0b159fd01bb66e5955f523af9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-acquire-arcellx-7-8-111541314.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-acquire-arcellx-7-8-111541314.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ACLX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:01:00+00:00",
    "headline": "Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel",
    "summary": "FOSTER CITY, Calif. & REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur",
    "url": "https://finance.yahoo.com/news/gilead-sciences-acquire-arcellx-maximize-110100514.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b63a1407-0fa9-31b6-b99c-6abe13bf4b4e",
      "content": {
        "id": "b63a1407-0fa9-31b6-b99c-6abe13bf4b4e",
        "contentType": "STORY",
        "title": "Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel",
        "description": "",
        "summary": "FOSTER CITY, Calif. & REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur",
        "pubDate": "2026-02-23T11:01:00Z",
        "displayTime": "2026-02-23T11:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/db916ee653d5bb61381083eaa5da9a52",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5endfg_bxOmc33HQNN4A9Q--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/db916ee653d5bb61381083eaa5da9a52.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6zLN6Ivo8K2g33MEQDLvTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/db916ee653d5bb61381083eaa5da9a52.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-acquire-arcellx-maximize-110100514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-acquire-arcellx-maximize-110100514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:54:43+00:00",
    "headline": "Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion",
    "summary": "Feb 23 () - Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the ‌biopharma company said on Monday, as it looks to strengthen its lineup ‌of cancer treatments.",
    "url": "https://finance.yahoo.com/news/gilead-acquire-cancer-therapy-developer-125443430.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "4cbbf07b-7065-359a-91b5-a7d4fab54146",
      "content": {
        "id": "4cbbf07b-7065-359a-91b5-a7d4fab54146",
        "contentType": "STORY",
        "title": "Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion",
        "description": "",
        "summary": "Feb 23 () - Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the ‌biopharma company said on Monday, as it looks to strengthen its lineup ‌of cancer treatments.",
        "pubDate": "2026-02-23T12:54:43Z",
        "displayTime": "2026-02-23T12:54:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/f256a1a47d2fe1738b01fffb3fca569b",
          "originalWidth": 800,
          "originalHeight": 489,
          "caption": "Logos of Gilead at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zcDGAHCZfOvSH97aMngn0g--~B/aD00ODk7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/f256a1a47d2fe1738b01fffb3fca569b.cf.webp",
              "width": 800,
              "height": 489,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NTySBsnqUWmGkE3J_FhtqA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/f256a1a47d2fe1738b01fffb3fca569b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-acquire-cancer-therapy-developer-125443430.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-acquire-cancer-therapy-developer-125443430.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ACLX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:35:16+00:00",
    "headline": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
    "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
    "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
      "content": {
        "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
        "contentType": "STORY",
        "title": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
        "description": "",
        "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
        "pubDate": "2026-02-23T12:35:16Z",
        "displayTime": "2026-02-23T12:35:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "wall street stock market flag new york trading equity - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QVMgErJdOR7IkzCjRHm3pQ--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dimQxOClk1isv1IKNf9JtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:36:00+00:00",
    "headline": "Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion",
    "summary": "Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.",
    "url": "https://www.wsj.com/tech/biotech/gilead-sciences-to-buy-arcellx-in-deal-valued-at-7-8-billion-53d57e3a?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "00cc6205-8a93-30dd-993c-a13cc383aa2c",
      "content": {
        "id": "00cc6205-8a93-30dd-993c-a13cc383aa2c",
        "contentType": "STORY",
        "title": "Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion",
        "description": "",
        "summary": "Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.",
        "pubDate": "2026-02-23T11:36:00Z",
        "displayTime": "2026-02-23T11:36:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/00cc6205-8a93-30dd-993c-a13cc383aa2c/gilead-sciences-to-buy.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/94dafe9cc49c2e92186b7e8630400280",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uPkGk0hX1VNEmW9kJcQNgQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/94dafe9cc49c2e92186b7e8630400280.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5Qo1eXs8g.tTSvpsQSXIYQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/94dafe9cc49c2e92186b7e8630400280.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/tech/biotech/gilead-sciences-to-buy-arcellx-in-deal-valued-at-7-8-billion-53d57e3a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:32:02+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
    "summary": "↗️ Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
        "description": "",
        "summary": "↗️ Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
        "pubDate": "2026-02-23T11:32:02Z",
        "displayTime": "2026-02-23T11:32:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "UAL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]